Although the inhibition of monocyte/macrophage recruitment by chemokine targeting approaches such as blocking the CCL2/CCR2 axis with a CCR2 antagonist suppresses tumour growth [83] and potentiates the therapeutic effects of sorafenib in mouse models of HCC [84], using CCR2 antagonists as a monotherapy might not be as effective as initially thought, as compensatory TAM subsets such as KC-like TAMs can emerge [19]. The gene discussed is CCR2; the disease is hepatocellular carcinoma.